VUM02
/ Vcanbio Cell & Gene Engineering Corp
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
August 01, 2026
DEVIF-I: Safety, Tolerability and Efficacy of VUM02 Injection in Treatment of Idiopathic Pulmonary Fibrosis (IPF)
(clinicaltrials.gov)
- P1 | N=9 | Completed | Sponsor: Wuhan Optics Valley Vcanbiopharma Co., Ltd. | Recruiting ➔ Completed
Trial completion • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases
November 06, 2024
ESTEVS-I/II: A Phase I/II Trial of VUM02 Injection for Steroid-refractory Acute Graft-versus-host Disease (SR-aGvHD) Treatment
(clinicaltrials.gov)
- P1/2 | N=149 | Not yet recruiting | Sponsor: Wuhan Optics Valley Vcanbiopharma Co., Ltd.
New P1/2 trial • Acute Graft versus Host Disease • Graft versus Host Disease • Immunology
February 20, 2024
DEVIF-I: Safety, Tolerability and Efficacy of VUM02 Injection in Treatment of Idiopathic Pulmonary Fibrosis (IPF)
(clinicaltrials.gov)
- P1 | N=9 | Recruiting | Sponsor: Wuhan Optics Valley Vcanbiopharma Co., Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases
January 30, 2024
DEVIF-I: Safety, Tolerability and Efficacy of VUM02 Injection in Treatment of Idiopathic Pulmonary Fibrosis (IPF)
(clinicaltrials.gov)
- P1 | N=9 | Not yet recruiting | Sponsor: Wuhan Optics Valley Vcanbiopharma Co., Ltd.
New P1 trial • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases
1 to 4
Of
4
Go to page
1